読み込み中
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.
前日終値
$1.89
+$0.06 · +3.28%
日中の時刻はETです。市場データは遅延する場合があります。
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.
日中レンジ
現在 $1.89
52週レンジ
現在 $1.89
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
46
適正価値
センチメント
45
まちまち
リスク
63
高リスク
モメンタム
79
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.
日中レンジ
現在 $1.89
52週レンジ
現在 $1.89
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 5万 USD | 1.4万 USD | 15.5万 USD | 37.4万 USD | 18.1万 USD |
| 粗利益 | 5万 USD | 1.4万 USD | 15.5万 USD | 37.4万 USD | 18.1万 USD |
| 研究開発 | 2065.9万 USD | 3316.6万 USD | 2027.3万 USD | 1706.7万 USD | 2054.3万 USD |
| 販売・一般管理 | 1026万 USD | 948.3万 USD | 962.3万 USD | 925.8万 USD | 879.1万 USD |
| 営業費用 | 3091.9万 USD | 4264.9万 USD | 2989.6万 USD | 2632.5万 USD | 2933.4万 USD |
| 受取利息 | 85万 USD | — | — | — | — |
| 減価償却費と償却費 | 8.4万 USD | 55.3万 USD | 2974.1万 USD | 2595.1万 USD | 2915.3万 USD |
| 営業利益 | −3086.9万 USD | −4263.5万 USD | −2974.1万 USD | −2595.1万 USD | −2915.3万 USD |
| 純利益 | −4593.3万 USD | −4208.2万 USD | −3000.8万 USD | −2729.9万 USD | −3034万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$22.00
上昇余地（1064.02%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI112.76万0.00%2.3兆 USD0.03%$381.94+0.63%
Vanguard Extended Market ETFVXF45.08万0.00%954億 USD0.05%$235+0.80%
iShares Micro-Cap ETFIWC14.14万0.01%13.17億 USD0.60%$183+0.11%
U.S. Micro Cap Portfolio ETFDFMC1.06万0.00%75.58億 USD0.43%$57.813+0.20%
Dimensional - US Small Cap ETFDFAS7808.610.00%338.69億 USD0.31%$78.35+0.32%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCU.S. Micro Cap Portfolio ETFDFMCDimensional - US Small Cap ETFDFASAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
